ReviewJournal of cellular and molecular medicine2019
Protective role of melatonin in early-stage and end-stage liver cirrhosis.
Review in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Elevated diurnal CD36 expression disrupts the bile acid synthesis rhythm leading to cholestatic liver injury and inflammation via the HMGCR/CYP7A1 axis.Genes & diseases · 2026Article
- Serotonin, Kynurenine, and Indole Pathways of Tryptophan Metabolism in Humans in Health and Disease.Nutrients · 2026Review
- Serum melatonin predicts hepatic encephalopathy in patients with liver cirrhosis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Pharmacological Targeting of NRF2 Represents a Promising Therapeutic Approach for Pyroptosis-Related Non-Alcoholic Fatty Liver Disease.Current medicinal chemistry · 2026Review
- Therapeutic and chemopreventive potential of melatonin in liver diseases: targeting oxidative stress and inflammatory signaling.Frontiers in pharmacology · 2026Review
- Mangiferin: a novel hepatoprotective for liver cirrhosis via modulation of histological, cellular, biochemical, inflammatory markers and oxidative stress.BMC pharmacology & toxicology · 2025Article
- Rev‑erbα: The circadian guardian against NLRP3‑driven liver fibrosis.Molecular medicine reports · 2025Article
- Sleep disorders impact hormonal regulation: unravelling the relationship among sleep disorders, hormones and metabolic diseases.Diabetology & metabolic syndrome · 2025Review
- Micro- and nanoplastic toxicity in humans: Exposure pathways, cellular effects, and mitigation strategies.Toxicology reports · 2025Review
- Melatonin Interplay in Physiology and Disease-The Fountain of Eternal Youth Revisited.Biomolecules · 2025Review
- Involvement of SIRT1-mediated aging in liver diseases.Frontiers in cell and developmental biology · 2025Review
- Non-alcoholic fatty liver disease and sleep disorders.World journal of hepatology · 2024Review
- Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Article
- RETRACTED: Hepatoprotective Effects of Biochanin A on Thioacetamide-Induced Liver Cirrhosis in Experimental Rats.Molecules (Basel, Switzerland) · 2023Article
- Insight of Melatonin: The Potential of Melatonin to Treat Bacteria-Induced Mastitis.Antioxidants (Basel, Switzerland) · 2022Review
- NLRP3 Inflammasome and Pyroptosis in Liver Pathophysiology: The Emerging Relevance of Nrf2 Inducers.Antioxidants (Basel, Switzerland) · 2022Review
- Melatonin prevents oxidative stress, inflammatory activity, and DNA damage in cirrhotic rats.World journal of gastroenterology · 2022Article
- Melatonin Modulates the Antioxidant Defenses and the Expression of Proinflammatory Mediators in Pancreatic Stellate Cells Subjected to Hypoxia.Antioxidants (Basel, Switzerland) · 2021Article
- Melatonin and its protective role in attenuating warm or cold hepatic ischaemia/reperfusion injury.Cell proliferation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver is composed of hepatocytes, cholangiocytes, Kupffer cells, sinusoidal endothelial cells, hepatic stellate cells (HSCs) and dendritic cells; all these functional and interstitial cells contribute to the synthesis and secretion functions of liver tissue. However, various hepatotoxic factors including infection, chemicals, high-fat diet consumption, surgical procedures and genetic mutations, as well as biliary tract diseases such as sclerosing cholangitis and bile duct ligation, ultimately progress into liver cirrhosis after activation of fibrogenesis. Melatonin (MT), a special hormone isolated from the pineal gland, participates in regulating multiple physiological functions including sleep promotion, circadian rhythms and neuroendocrine processes. Current evidence shows that MT protects against liver injury by inhibiting oxidation, inflammation, HSC proliferation and hepatocyte apoptosis, thereby inhibiting the progression of liver cirrhosis. In this review, we summarize the circadian rhythm of liver cirrhosis and its potential mechanisms as well as the therapeutic effects of MT on liver cirrhosis and earlier-stage liver diseases including liver steatosis, nonalcoholic fatty liver disease and liver fibrosis. Given that MT is an antioxidative and anti-inflammatory agent that is effective in eliminating liver injury, it is a potential agent with which to reverse liver cirrhosis in its early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.